Survival and prognostic factors after bone marrow transplantation in adults with hematologic cancer : a retrospective study of 453 cases in an iranian population from 2007 to 2016

Publish Year: 1396
نوع سند: مقاله کنفرانسی
زبان: English
View: 366

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

NASTARANCANSER03_047

تاریخ نمایه سازی: 7 اسفند 1396

Abstract:

Hematologic cancers are cancers of the blood, bone marrow, and lymph nodes that include leukemia, lymphoma, and myeloma. A bone marrow transplant ( stem cell transplant) is a treatment forhematologic cancers. Determining the survival rate of patients with hematologic cancers after bone marrow transplantation is important. The aim of this study is to determine survival rate and the factorsinfluencing predicted survival of patients with hematologic cancers. In a retrospective study, a total of 453 patients 16 to 67 years of with hematologic cancers who had received bone marrow transplantation,registered in Bone Marrow Transplantation Research Center (from 2007 to 2016), Taleghani hospital, Tehran, Iran entered to this study. In this study, all of the diagnosed patients with Multiple Myeloma(MM), Non-Hodgkin’s lymphoma(NHL), Hodgkin’s disease (HD), Acute myeloid leukemia(AML) and Acute lymphoblastic leukemia(ALL) were entered into the analysis. Also, demographic and clinical features including age, sex, blood group, white blood cell (WBC) count at the time of diagnosis, CD34+, body surface, and the final status (alive or dead) were collected. Survival analysis was performed using parametric log-normal moled. The analysis was carried out using STATA, version11, and P-value less than 0.05 considered as the significance level. The result indicated that the mean age of the patients at diagnosis was 39.30 ± 13.35 years (range, 16-67 years) and 213 patients (44.7%) were male. Blood group for 136 (30%) patients was A, 99 (21.9%), 38 (8.4%), and 161 (35.5%) were B, AB and O, respectively. Also, 155(34.2%) was MM, 53(11.7%), 56(12.4%) and 34(7.5%) were NHL, AML and ALL, respectively. The mean (± standard deviation) survival time after Bone marrow transplantation was 78.42±2.59 months. NHL, AML, ALL and age were independent prognostic factors, according to log-normal moled. According to these data and based on parametric log-normalmoled, we found out that only age and the three morphology for hematologic cancer which include NHL, AML, ALL have a significant effect on patients survival after transplantation of bone marrow

Keywords:

Blood Cancer , Cell and Cancer , Cancer Stem Cells , Stem Cells and Cancer , Cancer Treatment and Management

Authors

Soraya Moamer

Department Of Biostatistics, Faculty Of Paramedical Sciences, Shahid Beheshti University Of Medical Sciences, Tehran, Iran

Ahmad Reza Baghestani

Physiotherapy Research Center, Department Of Biostatistics, Faculty Of Paramedical Sciences, Shahid Beheshti University Of Medical Sciences, Tehran, Iran

Maryam Dehghani

Department Of Biostatistics, Faculty Of Paramedical Sciences, Shahid Beheshti University Of Medical Sciences, Tehran, Iran)

Abbas Hajifathali

Hematopoeitic Stem Cell Research Center, Shahid Beheshti University Of Medical Sciences, Tehran, Iran